Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

GSK to acquire US oncology specialist for cancer assets

PUBLIC · GSKSep 07, 2026•about 10 hours ago

Acquiring Company

GSK plc

Acquired Company

a United States-based clinical-stage oncology specialist

PhiladelphiaPalo AltoManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnology Research

Description

GSK plc is set to acquire a United States-based clinical-stage oncology specialist. This acquisition aims to enhance GSK's oncology pipeline with late-stage lung-cancer therapies. The move reflects GSK's strategic commitment to strengthen its presence in the precision cancer treatment market.

Company Information

Company

GSK plc

Location

Philadelphia, Pennsylvania, United States

About

GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. The company is dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. GSK focuses on a range of health needs, including respiratory diseases, and has a commitment to develop life-saving medications and preventative treatments.

Don't miss GSK plc's next move

Get an email the moment GSK plc makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Agam
Likely contact at this company
••••••••@••••••••

See Agam's verified email →

Anshuman
Senior decision-maker at this company
••••••••@••••••••

See Anshuman's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for GSK plc's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired a United States-based clinical-stage oncology specialist?

a United States-based clinical-stage oncology specialist was acquired by GSK plc, based in Philadelphia. The deal was reported on September 7, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.

When did GSK plc acquire a United States-based clinical-stage oncology specialist?

GSK plc's acquisition of a United States-based clinical-stage oncology specialist was reported on September 7, 2026. GSK plc is set to acquire a United States-based clinical-stage oncology specialist. This acquisition aims to enhance GSK's oncology pipeline with late-stage lung-cancer therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does a United States-based clinical-stage oncology specialist do?

This oncology specialist is focused on developing innovative therapies for cancer treatment. With a concentration on precision medicine, it targets specific cancer pathways to develop effective treatments. It is publicly traded (GH), operating in Biotechnology Research, and is based in Palo Alto.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.